A Pharmacist Intervention to Improve Mother and Child Health

NCT06073054 | Completed Results

• 2 other identifiers: 2023053221UM1TR004403-01
• Study Type: interventional
• Target: 25
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this clinical trial is to learn if a research pharmacist can improve the health of new mothers and their babies. The main questions it aims to answer are:

• Will postpartum women who had elevated blood pressure during pregnancy be willing to participate in the study, talk to a pharmacist about their health and the health of their child, and text us their blood pressure measurements?
• Will contact with the pharmacist improve the health of the mother and/or the child? Participants will:
• complete a baseline demographic survey,
• be given a blood pressure cuff and taught how to use it,
• be asked to text us their blood pressure values 2 times per day for 7 days after enrollment,
• complete a phone call with a pharmacist discussing their health and the health of their baby,
• text us their blood pressure 1 time per day for 3 days 1 month after enrollment,
• have a 1 month follow-up phone call with the research pharmacist, and
• complete an exit survey to provide feedback about the study.

Conditions

Hypertension

Outcome Measures

Primary Outcomes (4)

• Number of Participants Who Talk to Research Pharmacist

  We will calculate the number of participants who talk to the research pharmacist during the course of the intervention.

  Through study completion, an average of 30 days

• Number of Participants Who Return BP Measurements

  We will calculate the number of participants who return at least one blood pressure measurement via text message.

  Through study completion, an average of 30 days

• Percentage of Well-Child Visits Attended

  We will calculate the percentage of well-child visits that are attended by each family.

  Through study completion, an average of 30 days

• Percentage of Vaccinations Received

  We will calculate the percentage of vaccinations received by each child.

  Through study completion, an average of 30 days

Secondary Outcomes (3)

• Number of BP Measurements Submitted

  Through study completion, an average of 30 days

• Blood Pressure Control

  Through study completion, an average of 30 days

• Number of Participants Satisfied With the Study

  Through study completion, an average of 30 days

Study Arms (1)

Research Pharmacist Monitoring

EXPERIMENTAL

The pharmacist will help the mother find a primary care physician if she doesn't have one, obtain health insurance if she doesn't have any, and discuss any health-related information about herself or her child, as needed. These pharmacist interactions will occur 7 days after baseline and again 1 month later (the participant will be asked to measure and text their blood pressure again 1 time per day for 3 days during the follow-up month). If the participant's blood pressures become elevated, the pharmacist will provide behavioral and lifestyle interventions to attempt to lower the blood pressure. They may also recommend medications to the participant's physician. The pharmacist will have access to the participant's electronic medical record to obtain any blood pressure-related medications that the mother is prescribed as well as throughout the follow up to ensure any health-related conditions can be discussed, as necessary.

Behavioral: Research Pharmacist

Interventions

Research Pharmacist BEHAVIORAL

The goal of this intervention is to determine if contact with the research pharmacist will improve the health of the mother and/or child.

Research Pharmacist Monitoring

Eligibility Criteria

• Age: 18 Years - 55 Years
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• biological mother of a baby attending a 1-week to 6-month well-child visit,
• received prenatal care at University of Iowa Hospitals and Clinics,
• had at least 2 elevated blood pressures (\>= 130 mmHg systolic or \>= 80 mmHg diastolic) during pregnancy,
• owns a smartphone

You may not qualify if:

• arm circumference \> 17 inches,
• prisoner status
• unable to provide own written informed consent

Sponsors & Collaborators

• University of Iowa: lead
• National Center for Advancing Translational Sciences (NCATS): collaborator

Study Sites (1)

University of Iowa Hospitals and Clinics

Iowa City, Iowa, 52242, United States

Location

MeSH Terms

Conditions

Hypertension

Condition Hierarchy (Ancestors)

Vascular Diseases; Cardiovascular Diseases

Results Point of Contact

• Title: Linnea Polgreen
• Organization: University of Iowa

linnea-polgreen@uiowa.edu

(319) 384-3024

Study Officials

• Hao Tran, MD

  University of Iowa

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: No
• Restrictive Agreement: No

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: SCREENING
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Clinical Assistant Professor

Study Record Dates

• First Submitted: September 22, 2023
• First Posted: October 10, 2023
• Study Start: January 30, 2024
• Primary Completion: July 10, 2024
• Study Completion: July 10, 2024
• Last Updated: August 29, 2025
• Results First Posted: August 29, 2025

Record last verified: 2025-08

Locations

US (1)